Georgia vs Kyrgyzstan: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Georgia
- Kyrgyzstan
How they compare
Kyrgyzstan currently reports 473.11 deaths against 391.52 deaths in Georgia, a difference of 81.59 deaths.
That makes Kyrgyzstan's figure about 1.2 times Georgia's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Kyrgyzstan ahead.
Georgia ranks 97th and Kyrgyzstan ranks 95th of 157 countries.
Across the 4 decades both report, Georgia averaged higher in 2 and Kyrgyzstan in 1.
Head to head by decade
| Decade | Georgia | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 21.22 deaths | 6.55 deaths | 14.67 deaths | Georgia |
| 2010s | 188.92 deaths | 186.13 deaths | 2.79 deaths | Georgia |
| 2020s | 359.78 deaths | 412.22 deaths | 52.44 deaths | Kyrgyzstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Georgia or Kyrgyzstan?
- Kyrgyzstan, at 473.11 deaths against 391.52 deaths in Georgia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Georgia and Kyrgyzstan?
- 81.59 deaths, with Kyrgyzstan ahead.
- How many years of comparable data are there for Georgia and Kyrgyzstan?
- 35 years are reported by both, from 1990 to 2024.
- How do Georgia and Kyrgyzstan rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Georgia ranks 97th and Kyrgyzstan ranks 95th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.